|
1
|
Cohen S, Bacon BR, Berlin JA, et al:
National Institutes of Health State-of-the-Science Conference
Statement: ERCP for diagnosis and therapy, January 14–16.
Gastrointest Endosc. 56:803–809. 2002.PubMed/NCBI
|
|
2
|
Masci E, Mariani A, Curioni S and Testoni
PA: Risk factors for pancreatitis following endoscopic retrograde
cholangiopancreatography: a meta-analysis. Endoscopy. 35:830–834.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Donnellan F and Byrne MF: Prevention of
post-ERCP pancreatitis. Gastroenterol Res Pract. 2012:7967512012.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dumonceau JM, Andriulli A, Deviere J,
Mariani A, Rigaux J, Baron TH and Testoni PA; European Society of
Gastrointestinal Endoscopy. European Society of Gastrointestinal
Endoscopy (ESGE) Guideline: prophylaxis of post-ERCP pancreatitis.
Endoscopy. 42:503–515. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lee KT, Lee DH and Yoo BM: The
prophylactic effect of somatostatin on post-therapeutic endoscopic
retrograde cholangiopancreatography pancreatitis: a randomized,
multicenter controlled trial. Pancreas. 37:445–448. 2008.
View Article : Google Scholar
|
|
6
|
Andriulli A, Clemente R, Solmi L, et al:
Gabexate or somatostatin administration before ERCP in patients at
high-risk for post-ERCP pancreatitis: a multicenter,
placebo-controlled, randomized clinical trial. Gastrointest Endosc.
56:488–495. 2002. View Article : Google Scholar
|
|
7
|
Andriulli A, Solmi L, Loperfido S, et al:
Prophylaxis of ERCP-related pancreatitis: a randomized, controlled
trial of somatostatin and gabexate mesylate. Clin Gastroenterol
Hepatol. 2:713–718. 2004.PubMed/NCBI
|
|
8
|
Arvanitidis D, Anagnostopoulos GK,
Giannopoulos D, et al: Can somatostatin prevent post-ERCP
pancreatitis? Results of a randomized controlled trial. J
Gastroenterol Hepatol. 19:278–282. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bordas JM, Toledo-Pimentel V, Llach J,
Elena M, Mondelo F, Ginès A and Terés J: Effects of bolus
somatostatin in preventing pancreatitis after endoscopic
pancreatography: results of a randomized study. Gastrointest
Endosc. 47:230–234. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Persson B, Slezak P, Efendic S and
Häggmark A: Can somatostatin prevent injection pancreatitis after
ERCP? Hepatogastroenterology. 39:259–261. 1992.PubMed/NCBI
|
|
11
|
Poon RT, Yeung C, Liu CL, et al:
Intravenous bolus somatostatin after diagnostic
cholangiopancreatography reduces the incidence of pancreatitis
associated with therapeutic endoscopic retrograde
cholangiopancreatography procedures: a randomized controlled trial.
Gut. 52:1768–1773. 2003. View Article : Google Scholar
|
|
12
|
Poon RT, Yeung C, Lo CM, Yuen WK, Liu CL
and Fan ST: Prophylactic effect of somatostatin on post-ERCP
pancreatitis: a randomized controlled trial. Gastrointest Endosc.
49:593–598. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Guelrud M, Mendoza S, Viera L and Gelrud
D: Somatostatin prevents acute pancreatitis after pancreatic duct
sphincter hydrostatic balloon dilation in patients with idiopathic
recurrent pancreatitis. Gastrointest Endosc. 37:44–47. 1991.
View Article : Google Scholar
|
|
14
|
Cotton PB, Lehman G, Vennes J, et al:
Endoscopic sphincterotomy complications and their management: an
attempt at consensus. Gastrointest Endosc. 37:383–393. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cooper ST and Slivka A: Incidence, risk
factors, and prevention of post-ERCP pancreatitis. Gastroenterol
Clin North Am. 36:259–276. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gullo L, Priori P, Scarpignato C, Baldoni
F, Mattioli G and Barbara L: Effect of somatostatin 14 on pure
human pancreatic secretion. Dig Dis Sci. 32:1065–1070. 1987.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Karalis K, Mastorakos G, Chrousos GP and
Tolis G: Somatostatin analogues suppress the inflammatory reaction
in vivo. J Clin Invest. 93:2000–2006. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lai KH, Lo GH, Cheng JS, et al: Effect of
somatostatin on the sphincter of Oddi in patients with acute
non-biliary pancreatitis. Gut. 49:843–846. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Omata F, Deshpande G, Tokuda Y, et al:
Meta-analysis: somatostatin or its long-acting analogue,
octreotide, for prophylaxis against post-ERCP pancreatitis. J
Gastroenterol. 45:885–895. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang Z, Li W and Wu L: Could somatostatin
prevent post-ERCP pancreatitis or hyperamylasemia? A randomized,
double blind, controlled preliminary clinical trial. Gastrointest
Endosc. 71:AB2992010. View Article : Google Scholar
|
|
21
|
Testoni PA, Giussani A, Vailati C, Testoni
S, Di Leo M and Mariani A: Precut sphincterotomy, repeated
cannulation and post-ERCP pancreatitis in patients with bile duct
stone disease. Dig Liver Dis. 43:792–796. 2011. View Article : Google Scholar : PubMed/NCBI
|
